Antibody Technology Companies 2010 - A systematic guide through the landscape of antibody technologies and their providers
The report "Antibody Technology Companies 2010 - A systematic guide through
the landscape of antibody technologies and their providers" provides a
description and assessment of antibody technologies and their corporate
providers as of November 2010. The report describes and analyzes the market
size of therapeutic monoclonal antibodies and Fc-fusion proteins in 2009.
Characteristics of approved antibody-based products regarding identification,
construction and manufacturing are evaluated as a basis for relevant antibody
technologies in 2010. Systematic profiles of 96 companies engaged in antibody
technologies serve as the basis to present in a structured manner four
clusters of platform technologies (generation, optimization, novel constructs,
expression/manufacturing). The report serves as a systematic guide through the
landscape of companies with antibody technologies for those in search of
service providers or partners for collaboration or licensing.
Background
As of October 2010, 34 original therapeutic monoclonal antibodies and
Fc-fusion proteins are marketed with 2009 sales exceeding US$ 45.4 bln. Thus,
antibodies as a therapeutic modality and technology have matured and
availability of new technologies as well as patent expirations offer a
multitude of new options when designing an antibody-based product. While the
established providers of transgenic mice have been acquired by Big
Pharma/Biotech, a plethora of new antibody technologies appeared. Although
this landscape of technologies for antibody lead generation and optimization,
creation of combinatorial biologics and for expression/manufacturing offers an
unprecedented range of possibilities, the selection of the most robust and
adequate technologies fitting fitting to the product target profile has become
more difficult than ever.
Scope of the report
Antibody market 2009
Technology analysis of 37 approved therapeutic antibody-based products
Profiles of 96 antibody technology companies
Antibody technology assessment
Antibody pipelines of technology companies
Overview of landscape of antibody technologies
Guide to identify suitable technologies and providers
Index
Overview
Market Size of Therapeutic Monoclonal Antibodies and Fc-Fusion Proteins in
2009
Characteristics of Approved Therapeutic Monoclonal Antibodies and
Fc-Fusion Proteins
Platform Technologies for the Generation of Novel Therapeutic
Antibody-based Products
Platform Technologies for the Optimization of Novel Therapeutic
Antibody-based Products
Platform Technologies for Products beyond Monoclonal Antibodies
Platform Technologies for the Expression and Manufacturing of Novel
Therapeutic Antibodies and Antibody-based Products
2 Market Size of Therapeutic Monoclonal Antibodies and Fc-Fusion Proteins
in 2009
3 Characteristics of Approved Therapeutic Monoclonal Antibodies and Fc-
Fusion Proteins
4 Platform Technologies for the Generation of Novel Therapeutic
Antibodybased Products
4.1 In vivo generation of antibodies
4.2 In vitro generation of antibodies
4.3 Outlook
5 Platform Technologies for the Optimization of Novel Therapeutic
Antibodybased Products
5.1 Use of natural immunoglobulin variants
5.2 Mutated immunoglobulins
5.3 Glcyo-engineering
5.4 Improvement of pharmaceutical quality
5.5 Outlook
6 Platform Technologies for Products beyond Monoclonal Antibodies
6.1 Oligoclonal antibodies
6.2 Engineering of novel antibody-based products
6.3 Outlook
7 Platform Technologies for the Expression and Manufacturing of Novel
Therapeutic Antibodies and Antibody-based Products
7.1 Mammalian cells
7.2 Other eukaryotic systems
7.3 Yeast expression
7.4 Bacterial expression
7.5 Outlook
Tables
Table 1: Sales of Therapeutic Monoclonal Antibodies and Fc-Fusion Proteins
in 2009 with Source of Information
Table 2: Sales of Therapeutic Monoclonal Antibodies and Fc-Fusion Proteins
in 2009 by Product
Table 3: Sales of Therapeutic Monoclonal Antibodies and Fc-Fusion Proteins
in 2009 by Therapeutic Area
Table 4: Sales of Therapeutic Monoclonal Antibodies and Fc-FusionProteins
in 2009 by Target
Table 5: Characteristics of Approved Therapeutic Monoclonal Antibodies and
Fc-Fusion Proteins
Table 6: Generation of Monoclonal Antibodies in vivo
Table 7: Generation of Monoclonal Antibodies by B-cell Isolation
Table 8: Generation of Monoclonal Antibodies in vitro
Table 9: Generation of Monoclonal Antibodies in Cells in vitro
Table 10: Modification of Monoclonal Antibodies for Function - Protein
and Glyco-Engineering
Table 11: Improvement of Pharmaceutial Quality of Antibodies
Table 12: Oligo- and Polyclonal Antibodies
Table 13: Novel Antibody-derived Formats by Protein Engineering
Table 14: Chemical and Protein Conjugates of Antibodies
Table 15: Automation of Antibody Lead Identification and Optimization
Table 16: Antibody: Druggability, Cross-Reactivity, Targe Discovery and
Others
Table 17: Expression and Manufacturing of Monoclonal Antibodies
Figures
Figure 1 Evolution of the Productivity of Mammalian Cell Culture
Figure 2 Calculation of Cost Structure for a Mammalian Cell Culture
Process of a Recombinant Monoclonal Antibody - part I
Figure 3 Calculation of Cost Structure for a Mammalian Cell Culture
Process of a Recombinant Monoclonal Antibody - part II
ADDENDUM
Company Profiles
4-Antibody
Abcheck
Abeome
Ablexis
Ablynx
AdAlta
Adimab
Affimed Therapeutics
Affitech
Alder Biopharmaceuticals
Alligator Biosciences
Ambrx
AnaptysBio
Antitope
arGEN-X
Armagen Technologies
Avanir Pharmaceuticals
Avipep
BioAtla
BioInvent
Biolex Therapeutics
Biosite
Biotecnol
Bristol-Myers Squibb (Medarex)
Calmune
Cephalon (Arana Therapeutics)
Chiome Bioscience
Crescendo Biologics
CytomX
Cytos
Discerna
Dyax
Elusys Therapeutics
Emergent Biosolutions (Trubion Pharmaceuticals)
Epitomics & Apexigen
Epivax
Esbatech & Delenex
Evec
ExcelImmune
f-star
Ganymed Pharmaceuticals
Genexine
Genmab
GlaxoSmithKline (Domantis)
Glycotope
GTC Biotherapeutics
Immunocellular Therapeutics
Immunogen
InNexus
InterVexion Therapeutics
Johnson & Johnson (Crucell)
Kalo Bios
Kenta Biotech
Kolltan
Kyowa Hakko Kirin (BioWa)
Lonza
MabCure
Macrogenics
MAT Biopharma
Merck & Co (GlycoFi)
Merrimack Pharmaceuticals
Merus
Micromet
Millegen
Morphosys
Morphotek
MSM Protein Technologies
Nascent Biologics
Neurimmune
North Coast Biologics
Open Monoclonal Technology (OMT)
OriGene Technologies
Oxford Biotherapeutics
Patrys
Pepscan Therapeutics
Pfizer (CovX)
Philogen
Planet Biotechnology
Regeneron
Sea Lane Biotechnologies
Seattle Genetics
Sloning Biotechnology
Sorrento Therapeutics
Symphogen
Synageva
Syntarga
Theraclone
Trellis
TRION Pharma
Vaccinex
Vivalis
Viventia Biotechnologies
XBiotech
Xencor
XOMA
Xori
Antibody Technology Companies 2010 published by La Merie Publishing in November 1, 2010. This report consists of 283 pages and the price starts from US $ 1394.
